FDA Approves First Gene Therapy for Pediatric Sanfilippo Syndrome Type A Patients
The U.S. Food and Drug Administration (FDA) has approved Fayuvi, the first gene therapy intended for pediatric patients with MPS IIIA, or Sanfilippo syndrome type A. This approval is specific to treatment in healthcare environments prepared to handle infusion reactions. This regulatory milestone provides a new clinical option targeting a rare pedia...
- Published date: 20-09-2026 10:03 AM
The U.S. Food and Drug Administration (FDA) has granted approval for Fayuvi, marking a significant advancement as the first gene therapy indicated for pediatric patients diagnosed with MPS IIIA, commonly known as Sanfilippo syndrome type A.
This approval represents a milestone in clinical care for affected pediatric populations, providing a novel therapeutic option tailored specifically to this rare genetic condition.
Administration of Fayuvi is designated for healthcare settings equipped to manage potential infusion reactions, ensuring patient safety is prioritized during treatment.
The FDA's decision underscores the ongoing commitment to enhancing therapeutic options through innovative medical interventions for rare pediatric disorders.